| Description | oxepinac is an effective and well-tolerated compound for the treatment of painful osteoarthritis. oxepinac has no teratogenic effect on mouse and rabbit fetuses in animal experiments. |
| In vivo | 对oxepinac 的致畸性影响在小鼠和兔子上进行了研究。在器官形成期间，oxepinac通过口服方式分别给予怀孕的小鼠和兔子，小鼠的剂量为每天3、30和90mg/kg，兔子的剂量为每天3、10和20mg/kg。研究结论显示，oxepinac对小鼠和兔子胎儿无致畸作用。此外，给予怀孕小鼠oxepinac不会对其幼崽的产后发展产生不利影响。[1] |
| Target activity | Aldose reductase (rabbit lens):0.33 μM |
| molecular weight | 268.26 |
| Molecular formula | C16H12O4 |
| CAS | 55689-65-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (205.02 mM) |
| References | 1. Arauchi T, et al. Teratogenicity study of oxepinac in mice and rabbits. Arzneimittelforschung. 1978;28(3):451-455. 2. Sasaki S. Multi-centered clinical evaluation of oxepinac against peripheral arthropathy particularly osteoarthritis. Arzneimittelforschung. 1978;28(3):462-468. 3. Nomura M, et al. Acute, subacute and chronic toxicity of oxepinac. Arzneimittelforschung. 1978;28(3):445-451. |